Drugs are frequently prescribed to patients with the aim of improving each patient's medical state, but an unfortunate consequence of most prescription drugs is the occurrence of undesirable side effects. Side effects that occur in more than one in a thousand patients are likely to be signalled efficiently by current drug surveillance methods, however, these same methods may take decades before generating signals for rarer side effects, risking medical morbidity or mortality in patients prescribed the drug while the rare side effect is undiscovered. In this paper we propose a novel computational meta-analysis framework for signalling rare side effects that integrates existing methods, knowledge from the web, metric learning and semi-supervised clustering. The novel framework was able to signal many known rare and serious side effects for the selection of drugs investigated, such as tendon rupture when prescribed Ciprofloxacin or Levofloxacin, renal failure with Naproxen and depression associated with Rimonabant. Furthermore, for the majority of the drug investigated it generated signals for rare side effects at a more stringent signalling threshold than existing methods and shows the potential to become a fundamental part of post marketing surveillance to detect rare side effects.
occur for drugs that are rarely prescribed or rare ADRs may go unnoticed by medical practitioners and may cause morbidity or mortality in patients that could have been prevented with more efficient drug surveillance methods. For example, it took 23 years before there was sufficient evidence that the drug Tamoxifen used to treat breast cancer caused endometrial cancer in about 1 in 6000 patients [11] [12] .
Current methods to discover rare ADRs often involve using a Spontaneous Reporting System (SRS) database that contains a collection of voluntary suspected drug and ADR reports, such as the database containing information from the UK yellow card scheme. The algorithms that signal ADRs by mining SRS databases calculate a measure of how disproportionally more often the medical event is reported with a specific drug of interest compared with any drug. The frequently implemented measures of disproportionality involve using standard epidemiology measures [13] , estimating the information component using a neural network approach [14] or calculating a modified version of the relative risk by applying a Bayesian model [15] . SRS databases combine reports of possible ADRs from a large population enabling the identification of possible ADR signals more efficiently, but they are known to suffer from underreporting [16] and this causes a lag in the time it takes to confidently signal a potential ADR. The under-reporting may also prevent the detection of rare ADRs, as these ADRs may never be suspected and therefore never be reported to an SRS database.
A potential new way to detect the rare ADRs that cannot be identified by doctors or by current methods applied to SRS databases is to use The Health Improvement Network (THIN) database (www.thinuk.co.uk), an Electronic Healthcare Database (EHD) containing complete UK General Practice records for registered patients. The THIN database contains all medical events (such as illnesses, laboratory results, signs and symptoms or administrative events) that a doctor is informed of for a patient as well as their complete prescription histories. Therefore, any rare ADRs that are serious enough to be reported to a doctor are more likely to be detected at an earlier point in time by applying a suitable data mining method on the THIN database rather than mining the SRS databases.
Existing methods developed for the EHDs are often disproportionality based methods (methods that contrast how often the event of interest occurs after the specified drug relative to how often the event of interest occurs after any drug) similar to the SRS methods [17] [18] [19] or association rule mining methods [20] [21] [22] . As EHDs do not contain links between drugs and suspected ADRs these are often inferred by investigating medical events that occur within some time period around a drug, but many of these medical events are linked to the cause of taking the drug and these 'therapeutically related' medical events present a major issue with the majority of the existing methods. It has been demonstrated that these existing methods are currently not suitable for signalling rare ADRs [23] . However, it is the rare ADRs that are unlikely to be detected by mining SRS databases, due to under-reporting, so developing an algorithm that can signal rare ADRs using the THIN database would be beneficial.
In this paper we develop a novel computational meta-analysis framework that integrates the existing methods (MUTARA, HUNT, OE ratio, see section III-A) and uses information obtained from the internet to efficiently and accurately identify rare ADRs that occur immediately or shortly after a drug is prescribed. The framework uses the dependency measures obtained from some of the existing electronic healthcare based methods and novel values of interest as attributes for each medical event that occurs within a 30 day period after the drug of interest is prescribed for any patient. After the attributes are generated for each medical event we label some of the medical events by extracting information from the internet informing us of the indicator events and known ADRs for the drug of interest. The unlabelled medical events then have labels assigned by applying metric learning and semi-supervised clustering.
Finally using the labels we develop a novel filter that removes medical events labelled as indicator events and then return the remaining medical events ordered by how often they occurred unpredictably within 30 days after the drug being investigated multiplied by weights based on their assigned labels.
The continuation of this paper is as follows, section II contains the background information on the THIN database and section III describes the problem formulation. This is followed by the description of the novel methodology we developed that is able to identify rare ADRs in section IV. Section V contains the results of comparing our novel algorithm with a section of existing methods for the detection of known rare ADRs and the discussion of these results is contained in section VI. The paper finishes with the conclusion and future work suggestions in section VII.
II. THIN DATABASE
The THIN database contains complete medical and prescription records for registered patients at participating general practices within the UK. The medical information is recorded into the THIN database by Read Codes that correspond to illnesses, so each Read Code is paired with the illness description.
Each Read Code is five elements long and the Read Codes have a tree structure. A level one Read Code has '.' as it's second element and corresponds to a very general description of an illness, for example 'A....' is a level one Read Code that corresponds to 'Infections'. A level two Read Code has '.' for it's third element but not for it's second element, an example is 'A1...' corresponding to 'Tuberculosis'. A level two Read Code is the child of the level one Read Code with a matching first element, so 'A1...' is the child of 'A....' (or A....' is the parent of 'A1...') and a child Read Code corresponds to a more specific Each drug is recorded into the THIN database by a drugcode (sometimes called the multilexeid) that is paired to the generic name. The drugcode consists of nine numbers and does not have a structure we use but the drugcode does specify the way the drug is ingested and the dosage. Each entry also includes the date that a Read Code or drugcode is recorded but does not contain the time. In this paper we used a subset of the THIN database containing records from 495 general practices. The subset contained approximately four million patients, over 358 million prescription entries and over 233 million medical event entries.
Patients can register at a new practice at any point over their lifetime and it has been shown that statistical studies using the THIN database will be biased if records from the first year after registration for a patient are included in the study [24] . The reason for this is that newly registered patients will need to inform their new doctor of any chronic illnesses they have, but these illnesses will be recorded on the day they inform the doctor of them rather than the actual day they were discovered. To prevent bias in this study we do not include the first year of a patient's medical records since registration. We also ignore the last 30 days of prescription records for each patient to reduce potential under reporting that may occur by including patients with less than 30 days of medical records after the first prescription of a drug . TABLE I: Examples of both a medical table and prescription table containing the patients records. The column patID is a unique reference corresponding to a patient, the age is the patient's age in days when the entry was recorded and the Read Code/drugcode is the reference to the specific medical event or prescription respectively. Drug Table  Medical Table   patID 
III. PROBLEM FORMULATION
The focus of this paper is to develop a method for detecting rare ADRs that occur shortly after prescription, so we can restrict our attention to the medical events that occur around the time of the drug prescription. In this paper we consider the natural numbers N to include 0 and use the interval [a...b] to be the interval of natural numbers from a to b ({n ∈ N : a ≤ n ≤ b}).
If we let M denote the set of Read Codes, D denote the set of drugcodes and Ω denote the set of patients in the THIN database then the sequence of Read Codes or the sequence of drugcodes for a patient can be represented as two discrete functions. The discrete function representing a patient's Read
Code sequence is a mapping f M : N × Ω → P(M ); f M (t, ω) → e ω,t where t is the age in days of the patient ω and e ω,t is the set of Read Codes that are recorded into the THIN database for patient ω when they are t days old. Similarly, the discrete function representing a patient's drugcode sequence 
The set of Read Codes that patient jj3 has recorded when he is 9999, 10000 and 10002 days old are
The reason f M (10002, jj3) = {} = ∅ is that patient jj3 does not have a Read Code recorded when he is 10002 days old. Similarly, the set of drugcodes that patient jj3 has recorded when he is 10000 and 10002 days old are f D (10000, jj3) = {979596759} and f D (10002, jj3) = {} = ∅ respectively.
The set consisting of every age in days where patient ω has a drugcode recorded into the THIN database is,
The set of all drugs that are prescribed for patient ω is the finite union of the set of drugcodes recorded daily for the patient while they are active in the THIN database, ∪f D (t, ω)
, so to determine the age that patient ω is first prescribed the drug of interest d * ∈ D we first find the set of ages that the patient was prescribed the drug,
and then define a new function α 1 : Ω × D → N ∪ {−1} :
that finds the minimum age that the patient is prescribed the drug or returns −1 if the patient has never been prescribed the drug. The set of patient's ages where the drug is prescribed for the first time in 13 months is determined by the functionα :
If a patient is not prescribed the drug then the function returns −1 otherwise it returns the set of ages in days that the patient took the drug and had a minimum of 386 days between previously taking the drug.
For the example entries in Table I , the set of ages in days that patient jj3 is prescribed any drugs is A D (jj3) = {10000, 20000, 20001} and the set of ages in days that the patient is prescribed the specific drugs 979596759 and 969686881 is α(jj3, 979596759) = {10000} and α(jj3, 969686881) = {20000, 20001} respectively. The minimum age that patient jj3 is prescribed 969686881 is α 1 (jj3, 969686881) = 20000 but as the patient aa2 is never prescribed the drug 969686881, α 1 (aa2, 969686881) = −1. The patient aa2 is prescribed the drug 912314611 four times (α(aa2, 912314611) = {15001, 15031, 15061, 25304})
with the first prescription occurring at 15001 days old (α 1 (aa2, 912314611) = 15001) but the drug was then repeated monthly two times and then the patient had a 10243 day break before being prescribed the drug for the final time, therefore the set of ages in days that patient aa2 is prescribed drug 912314611
for the first time in 13 months isα(aa2, 912314611) = {15001, 25304} as the instances when the drug was repeated after 30 days are not included.
In the continuation of this paper we will useα(ω, d * ) k to refer to the k th time patient ω is prescribed drug d * for the first time in 13 months, soα(ω,
where n is the total number of times patient ω is prescribed drug d * for the first time in 13 months (n =
Following on with our example,α(aa2, 912314611) 1 = 15001 andα(aa2, 912314611) 2 =
25304.
This then enables us to define a interval of interest around each time the patient is prescribed a drug for the first time in 13 months, for each
Equation (6) is defining a time interval centred around the K th time drug d * is prescribed for the first time in 13 months for patient ω determine by the integers t 1 and t 2 . For example, if we wanted to investigate the 30 days after a prescription we would use t 1 = 1 and t 2 = 30 and the time period around the first prescriptions in 13 months of drug 912314611 for patient aa2 would be T (aa2, 912314611, 1, 30 As the function f M (t, ω) returns a set of Read Codes that are recorded into the THIN database for patient ω when they are t days old, we can find the set of ages in days that ω has any Read Code recorded,
and the finite union over each
, is the set of all Read Codes that are recorded into the THIN database for the patient ω. It follows that ∪f M (t, ω)
is the set of all Read Codes that are recorded into the THIN database for the patient ω during the period of interest determined by t 1 and t 2 around the K th prescription of drug
is one if the patient ω has the Read Code e i recorded within the time period of interest around the first prescription of drug d * and zero otherwise. To determine the number of times the drug d * is prescribed to patient ω for the first time in 13 months and the Read Code e i is recorded within the time period of interest we define another functionĥ :
The total number of patients in the THIN database that have Read Code e i recorded within the time period of interest centred around the first prescription of drug d * is then,
and the total number of first times prescriptions of drug d * in 13 months where the Read Code e i is recorded within the time period centred around the prescription determined by t 1 and t 2 is,
A. Existing Algorithms
The observed to expected (OE) ratio [17] calculates the information component (IC) that looks at the disproportionality between how often a Read Code is recorded within some time period after the first prescription in 13 months of the drug of interest compared to how often it is recorded within the same time period after the first prescription in 13 months of any drug but also adds a bias lowering the IC value if the Read Code or drug is rare.
The function used to test if a set of medical events is empty is,Ĥ : P(M ) → {0, 1},
using the above function, we define the following values,
Where n d * ei (0, 30) is the number of times that event e i occurs in the month after a first prescriptions in 
and the IC(t 1 , t 2 , e i , d * ) value calculates how many first prescription in 13 months of drug d * have the
Read Code e i occurring between t 1 and t 2 days after divided by the expected value if the Read Code and drug occur independently,
The value of a half added to both the numerator and denominator in the IC(t 1 , t 2 , e i , d * ) value calculation creates a bias that causes the IC(t 1 , t 2 , e i , d * ) value to tend to zero when the Read Code or drug occurs rarely.
The IC ∆ is a measure that compares the IC(0, 30, e i , d * ) corresponding to the time period of a month after the first prescription in 13 months compared to the IC(−810, −630, e i , d * ) corresponding to a time period between 27 and 21 months prior to the prescription.
where, to the IC value the month prior to the prescription being higher than the month after prescription, or the IC value on the day of prescription being higher than a month after. In this paper we will use the IC ∆ (e i , d * ) as described above as an attribute for each possible drug and Read Code combination and use the Heaviside step function H : R → {0, 1},
to define the filter functions,
as two addition binary attributes.
The algorithm Mining Unexpected Temporary Association Rules given the Antecedent (MUTARA)
[21] applies a case control approach that estimates the background rate that the Read Code is recorded MUTARA and HUNT both investigate the Read Codes that occur during the month after the drug being studied is first prescribed to a patient or the union of the month after the first and second prescriptions of the drug if it is repeated within a month of the first prescription. Previously we defined α(ω, d * ) to be the ages in days that patient ω is prescribed the drug d * and α 1 (ω, d * )) to be the age in days that patient ω is first prescribed the drug d * , so the set α(ω, d * ) \ α 1 (ω, d * ) contains the ages that patient ω is prescribed drug d * except the age when they are first prescribe the drug. Using this we define a new function that returns the patient's age in days for the second time a drug is prescribed for a patient if this is within a month of the first prescription or the patient's age in days for the first time the drug is prescribed if the second prescription is not within a month of the first.
MUTARA uses patients that have not been prescribed the drug (so α 1 (ω, Putting this all together, the time interval of interest around the first prescription of drug d * for patients prescribed the drug or the time interval chosen at random for patients who have never been prescribed the drug used by MUTARA is,
where,
For patients who are prescribed the drug d * a filter is applied to ignore any 'expected' Read Codes that are recorded within the time interval of interest after the first prescription of the drug. A Read Code is 'expected' for the patient during the time interval of interest after the drug is prescribe if the patient also had the Read Code recorded within t 3 ∈ N days prior to drug being prescribed. We define this time interval prior to the prescription as, 
The Heaviside step function applied to α 1 (ω, d * ) returns 1 if patient ω has been prescribed the drug d * , as in that case α 1 (ω, d * ) > 0 or returns 0 if patient ω has never been prescribed the drug d * . MUTARA then calculates the unexpected-leverage as,
where the fraction of patients in the database who have the drug multiplied by the fraction of patients who have the Read Code recorded during their interval of interest is subtracted from the fraction of patients in the database who have the Read Code recorded within a month of the first time the drug is prescribed (or up to a month after the second prescription if the drug is repeated within a month).
HUNT calculates a similar value to the unexpected-leverage known as the leverage that does not include a filter to remove 'expected' Read codes based on a patient's history,
and
HUNT then ranks the Read Codes in descending order of the leverage to attain the leverage rank and in descending order of the unexpected-leverage to attain the unexpected-leverage rank and then calculates the rank ratio between the leverage rank and unexpected-leverage rank. Finally, HUNT returns the Read codes in descending order of this rank ratio.
B. Novel Algorithm Attributes
The attributes of interest for detecting ADRs are how many patients have the Read Code recorded a month prior to the first prescription compared with how many patients have it recorded a month after, Codes that are recorded on the same day as the drugcode could correspond to a serious ADR that occurs immediately or an indicator, this is why the day of prescription is not included in the above ABratios and instead is used as another attribute,
In previous methods there has been a patient level filter that removes medical events from a patient's sequence that occur 30 days after the drug if the patient also had the medical event shortly prior to the drug [20] . The justification for this is, if a patient had an illness shortly before the drug then having the illness repeated after the drug is unlikely to be an ADR. This inspires the third attribute that is based on the number of patients who have the Read Code recorded in the month after and also have it recorded during the month prior to the first prescription,
The final attributes of interest make use of the Read Code tree structure. When a patient first has an illness it is likely that not much detail is known, so a low level Read Code will probably be recorded into the THIN database, over time more information may be discovered about a patient's illness possibly due to laboratory results and this may then result in a more specified higher level Read Code being entered (a child of the original less detailed Read Code). As a consequence, it is common for higher level Read
Codes related to the cause of taking the drug to only be recorded after the drug, so to help distinguish between these and ADRs we calculate the Read Code after and before ratio when only considering the first two or three elements of a Read Code. For example, considering the first three elements of the Read Code, the Read Code A11ab becomes A11 and the ABratio lev3 is the number of patients that have a Read Code starting with A11 within the month after the first prescription of the drug divided by the number of patients that have a Read Code starting with A11 within the month prior to the first prescription of the drug. Similarly, the ABratio lev2 for a Read Code is the number of patients who have a Read Code with the same first two elements within a month after the first prescription divided by the number of patients who have a Read Code with the same first two elements within a month prior to the prescription.
Step 1 •Generate Read code attributes
Step 2 •Get labels for some Read codes
Step 3 •Apply distance metrix learning
Step 4 •Apply semi-supervised clustering Step5 •Filter and Order Read codes To calculate these attributes we first define an equivalence relationship, e i n ∼ e j if the first n elements of the Read Codes of e i and e j are the same. ADRs. The value of k will determine the filtering threshold and in this paper we consider the top 100
ranked Read Codes to be signalled by the algorithms.
A. Step 1
The first step of the DRESS algorithm is the generation of attributes for any Read Code that could be an ADR. This is accomplished by initially finding the set of all the Read Codes that are recorded within a month of the first prescription of d * for any patient, we denote this set of Read Codes by G. (16)- (17)). The data point
for each e i ∈ G is denoted by x i ∈ R 9 and is a vector corresponding to the attribute values. The set of data points is denoted by X = {x 1 , x 2 , ..., x n }, where the cardinality of the set G is n (|G| = n).
B. Step 2
As we are applying a semi-supervised approach, we need labels for some of the Read Codes. We have decided to have three different labels for each Read Code, one label representing Read Codes that are ADRs (known ADR), another label representing Read Codes that cause the drug to be taken by the patients (indicator) and the final label representing Read Codes that are not linked to the drug but just occur by chance (noise). The reason for choosing three labels is because there is information available to enable us to determine the labels for a sufficient number of Read Codes when using three labels.
We determined the Read Codes that are labelled as noise by using the hierarchal structure of the Read 
C. Step 3
After labelling some of the Read Codes we then applied the metric learning algorithm detailed in [26] . Letting S denote the set of all index pairs for Read Codes with the same label (e.g. if Read Codes corresponding to the data points x 1 and x 2 are both labelled as noise then (1, 2) ∈ S), D denote the set of all index pairs for Read Codes with a different label (e.g. if the Read code corresponding to data point x 1 is labelled as noise but the Read code corresponding to the data point x 5 is labelled as an indicator then (1, 5) ∈ D) and the inner product of two d × n real valued matrices, X, Y ∈ R d×n , is denoted by
where Tr(A) means the trace of the matrix A. The cone of positive semidefinite matrices is denoted by S d + . Given a pair of Read Code data points x i and x j generated in step 1, we calculate the matrix
Input :
• smoothing parameter µ > 0 (e.g., 10 −5 )
• tolerance value tol (e.g., 10 −5 )
• step sized {α t ∈ (0, 1) :
The distance metric learning algorithm from [26] When applied in the DRESS algorithm, the distance metric algorithm described in algorithm 1 finds a mapping from the space consisting of the attribute values found in step 1 to a different space that minimises the distance between two Read Codes with the same label and maximises the distance between two Read Codes with different labels. The mapping is, f :
, where S µ t is the 9 × 9 learned distance metric matrix,
D. Step 4
The constrained K-means algorithm [27] is applied to the Read Codes on their corresponding transformed data points determined by the distance metric learning algorithm above. The constrained Kmeans algorithm is a semi-supervised algorithm that fixes the class of the labelled Read Codes and uses these labelled Read Codes to calculate the initial cluster centres then iteratively assigns the non-fixed Read Codes into the cluster with the closest mean, with the means iteratively being recalculated until convergence.
When the DRESS algorithm is implemented, the set of data points input into the Constrained Kmeans algorithm is the set {f (x 1 ), f (x 2 ), ..., f (x n )}, the value of K input is 3 and the initial seeds are S 1 = {x i : x i is labelled as a known ADR}, S 2 = {x i : x i is labelled as an indicator} and S 3 = {x i :
x i is labelled as noise}.
Input : Set of data points X = {x 1 , x 2 , ..., x n }, x i ∈ R d , number of clusters K, the set
of X such that the KMeans objective function is optimised.
For x ∈ S, if x ∈ S h assign x to the cluster h (i.e., set X t+1 h ). For x ∈ S, assign x to the cluster h * (i.e., set X t+1 h * ), for h * = argmin In summary, the DRESS algorithm uses the semi-supervised clustering to filter Read Codes that have attributes that make them unlikely to be ADRs and then orders the remaining Read Codes by how often they occurred unexpectedly after the first prescription of the drug being investigated but also adds a weight so that Read Codes that have attributes similar to known ADRs are ranked higher.
V. RESULTS
We applied the DRESS algorithm to a range of drugs, some of which have been withdrawn from the market due to serious ADRs. Table II shows the rank that each data mining algorithm assigns for a known rare and serious drug and ADR pair. The table also states the cause for taking the drug (the indication), the year the drug was withdrawn and approximately how commonly the ADR occurs for patients prescribed the drug. In some cases the rare and serious ADR being investigated was listed as an ADR on the netdoctor website and to prevent any bias in the results for the DRESS algorithm, any labels for the Read Codes corresponding to the ADR being investigated were removed at the end of step 2, prior to the semi-supervised steps. So the Read Codes corresponding to the ADR being investigated were always unlabelled in the DRESS algorithm.
The DRESS algorithm had an average rank over the drug and ADR pairs of 143.75 and had the highest rank compared to all the other algorithms for 12 of the 16 drug and ADR pairs investigated. It was able to return a rank under 100 for 56.25% of the ADRs and all the ADRs had a rank below 500. In comparison the other methods had an average rank of 344.69, 791 and 2385.73 for the OE ratio, HUNT and MUTARA respectively. The OE ratio only returned a rank under 100 for 25% of the ADRs and only 6.25% of ADRs ranked by MUTARA and HUNT had a rank under 100. The existing methods for detecting ADRs using EHDs do not currently definitively detect ADRs, but rather, they can be considered to generate tentative ADR signals for the top k ranked medical events in their returned list. This is effectively filtering out all the medical events that are unlikely to be ADRs or the medical events without sufficient evidence (number of patients experiencing the event after the drug)
of being an ADR. The medical events with a rank greater than k are ignored and the medical events with a rank less than k (the signalled medical events) are investigated further to confirm if they are true ADRs.
Therefore, for an unknown ADR to be detected by these existing methods it needs to be signalled by being ranked in the top k medical events returned and the closer that the rank is to the value 1, the more likely it will be investigated further, even when low values of k are used. The results of this paper show that the existing methods are not able to rank the known rare and serious ADRs highly, so they would be unlikely to signal these for further investigation, but the DRESS algorithm was able to rank over 50% of these rare ADRs within the top 100 and would most likely signal these for further investigation. This implies that the DRESS algorithm is more suitable than existing methods for detecting rare ADRs and has the potential to discover many unknown rare ADRs.
The DRESS algorithm was unable to rank 'Naproxen and Hepatitis' and 'Nifedipine and weight increase' higher than the OE ratio, one reason for this is that the DRESS algorithm does not perform as well for medical events that have a high background rate as medical events that are common will have a greater number of patients experiencing the medical event in the month before the prescription and if the ADR is rare only one or two patients extra will have the medical event in the month after the prescription, so the ABratio will be close to one, but on the other hand, the OE ratio performs better for medical events with a high background rate as the bias in the IC calculation will have less impact.
It might be better to have two ADR clusters, one for the medical events that occur at a low background rate and another for the medical events that occur at a high background rate, but this may cause issue if there is not a sufficient number of Read Codes corresponding to known side effects, as if there are only a few Read Codes for the known side effects there may only be one to two labelled Read Codes in each cluster and this will be deleterious for the semi-supervised methods.
It may be argued that the DRESS algorithm can only be applied after many ADRs are known and this may prevent it efficiently detecting rare ADRs, but rare ADRs that occur less than 1 in 1000 patients generally need three of more ADR cases before there is satisfactory evidence to confirm the ADR and this requires thousands of patients having the drug. DRESS can be implemented after a few hundred patients have taken a drug as the obvious side effects will be known, so the constraint of requiring known ADRs will not reduce the efficiency of DRESS. It is worth noting that the current implementation of DRESS will not be as effective if a drug is generally safe and does not have many side effects, but this is not common and DRESS could be modified to use the positive effects of the drug as labelled medical events as the positive effects and side effects have similar attribute values as both should increase after the drug is taken.
The DRESS algorithm still highly ranks medical events related to the cause of the drug and removing these medical events would greatly improve the ability to detect rare ADRs with DRESS. The expect attribute has limitations as it only indicates if the patient had a repeat of a medical event and does not make use of the medical event relations within the THIN database to determine if a medical event is expected based on related medical events. For example, if a patient has 'a cold' then they are likely to experience 'a cough' if the illness progresses, but the expect attribute only says 'a cough' is expected if the patient has had 'a cough' shortly before and not if a predecessor medical event has occurred before.
To reduce the rank of medical events related to the cause of the drug a new attribute that uses sequential patterns to determine the expectedness of each medical event that occurs after the description could be used.
VII. CONCLUSION
In this paper we have described a novel methodology to detect rare ADRs that incorporates some existing methods (Observe Expected ratio, MUTARA and HUNT), information retrieval from the web, metric learning and semi-supervised clustering. The results suggest this methodology is able to detect rare and serious ADRs for the range of drugs chosen in the investigation and has the potential to help detect many currently unknown ADRs. The method is not able to remove all medical events related to the cause of taking the drug and future work should aim to prevent generating signals for these medical events by adding an additional attribute to the clustering that determines the expectedness of each medical event based on sequential patterns that can be mined from the whole database. Further work could also investigate different metric learning and semi-supervised clustering techniques. immediately occurring ADRs as well as congenital/perinatal or cancer events so we label these as noise.
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